FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283268482> ?p ?o ?g. }

• W4283268482 endingPage "731.e9" @default.
• W4283268482 startingPage "723" @default.
• W4283268482 abstract "Cirrhosis-related complications are a major burden. Rifaximin soluble solid dispersion (SSD) tablets (immediate-release [IR]; sustained extended-release [SER]) were designed to increase rifaximin water solubility. These analyses evaluate dosing for prevention of cirrhosis complication-related hospitalizations/mortality and overt hepatic encephalopathy (OHE) treatment.Two phase II, randomized, double-blind, placebo-controlled trials were conducted. Trial 1: outpatients with early decompensated cirrhosis randomized to placebo or rifaximin SSD once-nightly: IR 40 or 80 mg, SER 40 or 80 mg, or IR 80 mg plus SER 80 mg, for 24 weeks. Trial 2: inpatients with OHE randomized to lactulose plus placebo or rifaximin SSD: IR 40 mg once or twice daily or SER 80 mg once or twice daily for ≤14 days. Primary efficacy endpoint: time to cirrhosis complication-related hospitalization/all-cause mortality (Trial 1) or time to OHE resolution (Trial 2).In Trial 1 (n = 516), no significant difference in time to cirrhosis complication-related hospitalization/all-cause mortality vs placebo. In a post hoc analysis, time to all-cause hospitalization/all-cause mortality was improved with IR 40 mg vs placebo (15.4% [12/78] vs 27.7% [26/94]; P = .03). A Trial 2 prespecified interim analysis (n = 71) showed lactulose plus rifaximin SSD IR 40 mg bid significantly reduced median time to OHE resolution (21.1 hours) vs lactulose plus placebo (62.7 hours; P = .02). Trial 2 was subsequently terminated.Rifaximin SSD IR 40 mg may reduce hospitalizations in patients with cirrhosis and shorten duration of OHE during hospitalization-considered a negative finding, yet also hypothesis-generating. (ClinicalTrials.govNCT01904409; NCT03515044)." @default.
• W4283268482 created "2022-06-23" @default.
• W4283268482 creator A5016235995 @default.
• W4283268482 creator A5035384537 @default.
• W4283268482 creator A5039696464 @default.
• W4283268482 creator A5043752774 @default.
• W4283268482 creator A5044654584 @default.
• W4283268482 creator A5067770887 @default.
• W4283268482 creator A5070639714 @default.
• W4283268482 creator A5089881531 @default.
• W4283268482 date "2023-03-01" @default.
• W4283268482 modified "2023-10-01" @default.
• W4283268482 title "Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials" @default.
• W4283268482 cites W1964027278 @default.
• W4283268482 cites W1964051982 @default.
• W4283268482 cites W2003796334 @default.
• W4283268482 cites W2012746560 @default.
• W4283268482 cites W2018274907 @default.
• W4283268482 cites W2047740672 @default.
• W4283268482 cites W2077623116 @default.
• W4283268482 cites W2092488871 @default.
• W4283268482 cites W2099360240 @default.
• W4283268482 cites W2105932465 @default.
• W4283268482 cites W2138196119 @default.
• W4283268482 cites W2170325206 @default.
• W4283268482 cites W2409666333 @default.
• W4283268482 cites W2605087459 @default.
• W4283268482 cites W2809477369 @default.
• W4283268482 cites W2903823242 @default.
• W4283268482 cites W2943140621 @default.
• W4283268482 cites W2948306237 @default.
• W4283268482 cites W2966405517 @default.
• W4283268482 cites W2999277811 @default.
• W4283268482 cites W3028322855 @default.
• W4283268482 cites W3041160710 @default.
• W4283268482 cites W3089718558 @default.
• W4283268482 cites W3118456127 @default.
• W4283268482 doi "https://doi.org/10.1016/j.cgh.2022.05.042" @default.
• W4283268482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35750249" @default.
• W4283268482 hasPublicationYear "2023" @default.
• W4283268482 type Work @default.
• W4283268482 citedByCount "5" @default.
• W4283268482 countsByYear W42832684822022 @default.
• W4283268482 countsByYear W42832684822023 @default.
• W4283268482 crossrefType "journal-article" @default.
• W4283268482 hasAuthorship W4283268482A5016235995 @default.
• W4283268482 hasAuthorship W4283268482A5035384537 @default.
• W4283268482 hasAuthorship W4283268482A5039696464 @default.
• W4283268482 hasAuthorship W4283268482A5043752774 @default.
• W4283268482 hasAuthorship W4283268482A5044654584 @default.
• W4283268482 hasAuthorship W4283268482A5067770887 @default.
• W4283268482 hasAuthorship W4283268482A5070639714 @default.
• W4283268482 hasAuthorship W4283268482A5089881531 @default.
• W4283268482 hasBestOaLocation W42832684821 @default.
• W4283268482 hasConcept C126322002 @default.
• W4283268482 hasConcept C141071460 @default.
• W4283268482 hasConcept C142724271 @default.
• W4283268482 hasConcept C168563851 @default.
• W4283268482 hasConcept C203092338 @default.
• W4283268482 hasConcept C204243189 @default.
• W4283268482 hasConcept C204787440 @default.
• W4283268482 hasConcept C27081682 @default.
• W4283268482 hasConcept C2777214474 @default.
• W4283268482 hasConcept C2777288759 @default.
• W4283268482 hasConcept C2777448540 @default.
• W4283268482 hasConcept C2778889925 @default.
• W4283268482 hasConcept C2780325230 @default.
• W4283268482 hasConcept C501593827 @default.
• W4283268482 hasConcept C71924100 @default.
• W4283268482 hasConcept C86803240 @default.
• W4283268482 hasConcept C89423630 @default.
• W4283268482 hasConcept C90924648 @default.
• W4283268482 hasConceptScore W4283268482C126322002 @default.
• W4283268482 hasConceptScore W4283268482C141071460 @default.
• W4283268482 hasConceptScore W4283268482C142724271 @default.
• W4283268482 hasConceptScore W4283268482C168563851 @default.
• W4283268482 hasConceptScore W4283268482C203092338 @default.
• W4283268482 hasConceptScore W4283268482C204243189 @default.
• W4283268482 hasConceptScore W4283268482C204787440 @default.
• W4283268482 hasConceptScore W4283268482C27081682 @default.
• W4283268482 hasConceptScore W4283268482C2777214474 @default.
• W4283268482 hasConceptScore W4283268482C2777288759 @default.
• W4283268482 hasConceptScore W4283268482C2777448540 @default.
• W4283268482 hasConceptScore W4283268482C2778889925 @default.
• W4283268482 hasConceptScore W4283268482C2780325230 @default.
• W4283268482 hasConceptScore W4283268482C501593827 @default.
• W4283268482 hasConceptScore W4283268482C71924100 @default.
• W4283268482 hasConceptScore W4283268482C86803240 @default.
• W4283268482 hasConceptScore W4283268482C89423630 @default.
• W4283268482 hasConceptScore W4283268482C90924648 @default.
• W4283268482 hasFunder F4320308573 @default.
• W4283268482 hasIssue "3" @default.
• W4283268482 hasLocation W42832684821 @default.
• W4283268482 hasLocation W42832684822 @default.
• W4283268482 hasOpenAccess W4283268482 @default.
• W4283268482 hasPrimaryLocation W42832684821 @default.
• W4283268482 hasRelatedWork W1989507260 @default.
• W4283268482 hasRelatedWork W2091958019 @default.

• next